Among patients with erythrocyte EPA concentrations less than 0.82% at the beginning of the augmentation trial, the association between subsequent changes in depressive symptoms and EPA tissue concentrations will be markedly reduced by the introduction of changes in IL-1 beta, IL-10 and PGE2 into the model.